LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 613Memorial Sloan Kettering Cancer
Center (MSKCC), 370
MEN.SeeMultiple endocrine
neoplasia (MEN)
MEN2A, 354, 362
MEN2A syndrome, 354, 361
MEN I.SeeMultiple endocrine
neoplasia type 1 (MEN I)
MENIN gene, MEN1 and, 354,
362
Meningioma, 383, 388
treatment of, 386, 391
MEN1 syndrome, 354, 361, 394,
405
MENIN gene and, 354, 362
6-Mercaptopurine, 442
Mesna bladder protection, 125,
131
Mesothelioma
biphasic, 485
malignant, 483, 485
calretinin, 483, 485
epithelial, 483, 485
malignant peritoneal, 489, 494
peritoneal, 484, 485
pleural, 57, 63
poor prognostic indicators of,
483, 485
primary peritoneal, 490, 494
Meta-analysis, 190, 194
Metaphase, 17, 25
Metastasis(es)
progression genes, 22, 30–31
risk of, 22, 30
tumor cells in, 22, 30
virulence genes, 22, 31
Metastatic breast cancer, drug for,
118, 121
Metastatic cancer, treatment of,
509–514
Metastatic cecal adenocarcinoma,
UGT1A1∗28 polymorphism,
270, 276
Metastatic melanoma, surgical
resection for, 377, 380
Metastatic parathyroid carcinoma,
353, 360–361
Metastatic pheochromocytoma,
recurrent, 355, 362
Metastatic renal cell carcinoma,
treatment of
IL-2 in, 80, 83
sorafenib in, 80, 83
Metastatic thyroid carcinoma,
doxorubicin for, 353, 360
MET gene
amplification, 97, 101
hereditary papillary renal cancer
and, 280, 289Methadone, for bone pain from
prostate cancer, 564,
569–570
Methadone 20 mg, oral dose of,
562, 568
Methotrexate, 442
in acute lymphoblastic leukemia
treatment, 127, 132
doses of, 123, 129
Methotrexate therapy, 481
Methylation, 14
Metronidazole, for brain abscesses
in immunocompetent patients,
543, 548
Metronomic low-dose
chemotherapy, 21, 30
Mexiletine, 570
MF.SeeMycosis fungoides (MF)
MGUS.SeeMonoclonal
gammopathy of undetermined
significance (MGUS)
MIAME.SeeMinimum
Information About A
Microarray Experiment
(MIAME)
MIBG scans, for neuroblastoma,
409
Microarray technology, 2, 9
MicroRNA (miRNA), 3, 9
defined, 3, 9
miR-15a/16 cluster, 18
mRNA expression and, 18
Microsatellite instability (MSI), 3,
10, 137, 140, 161, 170, 269,
315, 323
defined, 11
5-fluorouracil treatment in, 4, 11
in gastric cancer, 237, 243
Minimum Information About A
Microarray Experiment
(MIAME), 9
miRNA.SeeMicroRNA (miRNA)
Mismatch repair (MMR), 269
protein expression, in colon
cancer, 123
Mithramycin, 361
Mitosis
cyclin B and, 17, 25
order of, 17, 25
Mitotane, 356, 362, 363, 522
Mitoxantrone, 95, 100
and acute cardiac toxicity, 531
Mixed cellularity (MC), 434
MMP.SeeMatrix
metalloproteinase-9 (MMP)
MMR.SeeMismatch repair
(MMR)
Molecular epidemiology and
genetic epidemiology, 70, 74Monoclonal gammopathy of
undetermined significance
(MGUS), 470
Moon facies, 517, 522
Morphine, adverse effects of, 564,
569
MP.SeeMelphalan and prednisone
(MP)
MPT.SeeMelphalan, prednisone,
and thalidomide (MPT)
MRI.SeeMagnetic resonance
imaging (MRI)
MSCC.SeeMalignant spinal cord
compression (MSCC)
MSH2 gene
HNPCC and, 269, 275
mutation, 150, 155, 156
MSI.SeeMicrosatellite instability
(MSI)
mTOR.SeeMammalian target of
rapamycin (mTOR)
Mucinous adenocarcinoma, of
appendix, 488, 493
Mucosal-associated lymphoid tissue
(MALT), 263, 267
characteristic of, 263, 267
Hashimoto’s thyroiditis and, 263,
267
lymphoma, 428
Mucositis, 447
Muir-Torre syndrome, 160, 274
Multidetector computed
tomography (MDCT), 165,
175
Multiple endocrine neoplasia
(MEN), 137, 140, 160
type 2 and prophylactic surgery,
80, 83
Multiple endocrine neoplasia type 1
(MEN I), 218, 225
Multiple myeloma, 465
allogeneic transplantation, 466,
471–472
bortezomib in, 126, 131, 465,
469
defined, 470
dexamethasone, 465, 469
HDCT in, 469
IgG kappa, 465
kappa/lambda light chain, 466,
472
lenalidomide, 465, 469
thalidomide, 465, 469
therapy for, 468
Myasthenia gravis, 217, 222, 224,
524
Mycosis fungoides (MF), 416
features of, 420, 433
systemic therapy of, 420, 433